Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with Erlotinib or Alectinib in NSCLC
NCT02013219Phase 1Completed
- Sponsor
- Roche
- Start
- Apr 2014
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of atezolizumab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Roche. Primary endpoints: Percentage of Participants with Dose-Limiting Toxicities at 28 days and Recommended Phase II Dose of Atezolizumab and Erlotinib/Alectinib at 28 days. Started Apr 2014; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02013219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013219.